• Explore /
  • Poster
  • / Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.

Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.

Abstract Poster

Authors

null

Angelina Tjokrowidjaja

NHMRC Clinical Trials Centre, Camperdown, NSW, Australia

Angelina Tjokrowidjaja , Chee Khoon Lee , Michael Friedlander , Val Gebski , Laurence Gladieff , Jonathan A. Ledermann , Richard T. Penson , Amit M. Oza , Jacob Korach , Tomasz Huzarski , Luis Manso , Carmela Pisano , Rebecca Asher , Nicoletta Colombo , Tjoung-Won Park-Simon , Keiichi Fujiwara , Gabe S. Sonke , Ignace Vergote , Jae-Weon Kim , Eric Pujade-Lauraine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Citation

J Clin Oncol 38: 2020 (suppl; abstr 6014)

DOI

10.1200/JCO.2020.38.15_suppl.6014

Abstract #

6014

Poster Bd #

185

Abstract Disclosures

Similar Posters

First Author: Mansoor Raza Mirza

First Author: Elena Ioana Braicu

First Author: Karen Anne Cadoo

First Author: Genevieve MacAulay Vacheresse